F-Prime Capital and Alkemi Growth Capital also participated in the round.
Doceree will use the funds to scale its global operations, expand partnerships, augment its product portfolio and advance the platform’s measurement and behavior lift capabilities to bring greater transparency to results.
The funding will also help it strengthen HCP communications for pharma and life sciences brands, agencies and health information technology platforms.
“It is critical for industry players like pharma companies and HCP-only platforms to understand and react to the digital touchpoints and behaviors of HCPs for delivering messages they resonate with,” says Harshit Jain, founder & global CEO, Doceree.
“Our identity resolution technology and tailored products for different markets that adhere to the country-specific regulations and guidelines make it easy for pharma brands to engage with HCPs on digital mediums, while enabling publishers to improve engagement on their platforms with relevant medical information from pharmaceutical and life sciences brands,” Jain said.
Discover the stories of your interest
Doceree uses a proprietary identity-resolution technology, ESPYIANTM, to enable targeted messaging to physicians.
The platform enhances engagement between pharma companies and their target audience through its global publisher network.
Founded in 2019 by Jain, a former physician who transitioned into the healthcare marketing space, Doceree empowers pharma brands and media agencies with solutions that seamlessly reach HCPs on professional HCP networks and within their digital workflow to achieve better patient health outcomes.
“Doceree is transforming the way digital interactions between pharmaceutical brands and prescribers are facilitated,” says Ashish Venkataramani, partner, Eight Roads Ventures.
